Market cap
$2,375 Mln
Revenue (TTM)
$13 Mln
P/E Ratio
--
P/B Ratio
5.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-80 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-5.4
-
Debt to Equity
0.2
-
Book Value
$1.6
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
91,100,400
7 Years Aggregate
CFO
$-315.60 Mln
EBITDA
$-375.19 Mln
Net Profit
$-404.55 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Provention Bio (PRVB)
| 136.3 | 4.6 | 186.8 | 396.6 | 27.4 | -- | -- |
|
BSE Sensex*
| -11.1 | -2.1 | -8.9 | -7.5 | 6.6 | 9.1 | 11.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|
|
Provention Bio (PRVB)
| 88.1 | -66.8 | 13.7 | 741.8 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Provention Bio (PRVB)
|
25.0 | 2,375.4 | 12.9 | -113.6 | -993.9 | 133.4 | -- | 5.3 |
| 0.5 | 16.7 | 48.3 | -23.3 | -42.2 | -89.5 | -- | 0.7 |
Shareholding Pattern
View DetailsAbout Provention Bio (PRVB)
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and... monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey. Read more
-
Co-Founder, Pres, CEO & Director
Mr. Ashleigh W. Palmer B.Sc., M.B.A.
-
Co-Founder, Pres, CEO & Director
Mr. Ashleigh W. Palmer B.Sc., M.B.A.
-
Headquarters
Red Bank, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Provention Bio (PRVB)
What is the current share price of Provention Bio Inc (PRVB) Today?
The share price of Provention Bio Inc (PRVB) is $24.98 (NASDAQ) as of 27-Apr-2023 09:30 EDT. Provention Bio Inc (PRVB) has given a return of 27.4% in the last 3 years.
What is the current PB & PE ratio of Provention Bio Inc (PRVB)?
Since, TTM earnings of Provention Bio Inc (PRVB) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-6.98
|
6.51
|
|
2021
|
-3.09
|
-1.21
|
|
2020
|
-8.94
|
-4.96
|
|
2019
|
-14.48
|
-7.73
|
|
2018
|
-1.47
|
0.65
|
What is the 52 Week High and Low of Provention Bio Inc (PRVB)?
The 52-week high and low of Provention Bio Inc (PRVB) are Rs -- and Rs -- as of 17-May-2026.
What is the market cap of Provention Bio Inc (PRVB)?
Provention Bio Inc (PRVB) has a market capitalisation of $ 2,375 Mln as on 27-Apr-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Provention Bio Inc (PRVB)?
Before investing in Provention Bio Inc (PRVB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.